Newly created treatments for high-risk COVID-19 patients have proved highly effective. Unfortunately, challenges with their distribution and administration have limited their use.
Much remains to be learned about this new condition affecting a growing number of children. However, it is hoped with increased vaccination and fewer cases of the SARS-CoV-2 virus, case numbers of MIS-C will also go down.
Discoveries about the types of immunity eventually led to the use of human antibodies to treat disease.
While there may be no “magic bullet” to treat cytokine storm, one widely used immunomodulatory agent in particular — polyclonal intravenous immune globulin (IVIG) purified from healthy donor plasma — is distinguished by the simple fact that it is anything but a narrowly targeted treatment.
Despite proof of lifesaving benefits of vaccines, parental hesitancy to immunizing their children is often fueled by the plethora of myths surrounding vaccine safety.
Beyond COVID-19 vaccines, research is showing potential for new vaccines to treat several other diseases.
With three vaccines in circulation and three more on the horizon, is the end of the COVID-19 pandemic in sight?
With trillions of viruses living in the human and other species’ microbiomes, the possibility of novel viruses such as COVID-19 emerging is high, but the threat they may pose is unknown.
What can be done in the event of a severe shortage of IG products, whose production is entirely reliant on a continuous supply of IgG-rich plasma donated at more than 800 dedicated U.S. collection facilities?
By raising awareness and developing tools to detect sepsis earlier, healthcare organizations save lives from this often-deadly infection.
To staunch the growing threat of antibiotic resistance, the medical profession is pivotal in properly prescribing antibiotics and educating patients about their appropriate use.
As Americans continue to grapple with the skyrocketing costs of prescription drugs, many are turning to other countries to access medications they need at prices they can afford.
